Item 5. Market for Registrant’s Common Equity
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Market Information
Our common stock trades on The Nasdaq Global Market under the symbol “ANIP.”
Stockholder Information
As of February 20, 2026, there were approximatel y 360 shar eholders of record of our common stock, which does not include stockholders that beneficially own shares held in a “nominee” or in “street” name, and six holders of record of Class C special stock.
Dividends
We have never declared or paid cash dividends on our common stock. We do not anticipate paying any cash dividends on our common stock in the foreseeable future.
Our shares of Series A Convertible Preferred Stock (the “PIPE Shares”) accrued dividends at 6.50% per year on a cumulative basis, payable in cash or in-kind, and also participated, on a pro-rata basis, in any dividends that would have been declared with respect to our common stock. We paid all PIPE Share dividends in cash. There were no shares of PIPE Shares outstanding as of December 31, 2025 as all of the PIPE Shares were converted to common shares during the third quarter of fiscal 2025, as the conditions for the conversion had been satisfied.
There were also approximately 11,000 shares of Class C special stock issued and outstanding as of December 31, 2025. Holders of class C special stock are not entitled to receive dividends or to participate in the distribution of our assets upon liquidation, dissolution, or winding-up the Company.
We currently intend to retain all remaining available funds and any future earnings to fund the development and growth of our business.
Recent Sales of Unregistered Securities
None.
Issuer Purchases of Equity Securities
Period Total Number
of Shares
Purchased (1)
Average Price
Paid per Share Total Number of
Shares Purchased as
Part of Publicly
Announced Plans or
Programs Maximum Number (or
approximate dollar
value) of Shares
that may yet be
Purchased Under the
Plans or Programs
October 1 - October 31, 2025 — $ — — $ —
November 1 - November 30, 2025 5,730 $ 84.02 — $ —
December 1 - December 31, 2025 1,594 $ 81.51 — $ —
Total 7,324 $ 83.47 —
(1) Shares purchased during the period were transferred to the Company from employees in satisfaction of minimum tax withholding obligations associated with the vesting of restricted stock awards during the period.
59
Table of Contents
Performance Graph
The graph below compares the five-year cumulative total stockholder ret urn on our common stock, the Nasdaq Stock Market (US) Index, and the S&P 600 Pharmaceuticals, Biotechnology & Life Sciences Index, as suming the investment of $100.00 on December 31, 2020, with dividends being reinvested. The stock price performance in the graph below is not necessarily indicative of future price performance.
60
Table of Contents
Item 6. Reserved
61
Table of Contents